These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26997452)

  • 21. The value of serial arteriography in osteosarcoma: delivery of chemotherapy, determination of therapy duration, and prediction of necrosis.
    Cullen JW; Jamroz BA; Stevens SL; Madsen W; Hinshaw I; Wilkins RM; Cullen P; Camozzi AB; Fink K; Peck SD; Kelly CM
    J Vasc Interv Radiol; 2005 Aug; 16(8):1107-19. PubMed ID: 16105923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significant immunohistochemical expression of human chorionic gonadotropin in high-grade osteosarcoma is rare, but may be associated with clinically elevated serum levels.
    Lee AF; Pawel BR; Sullivan LM
    Pediatr Dev Pathol; 2014; 17(4):278-85. PubMed ID: 24856811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spontaneous necrosis and additional tumor necrosis induced by preoperative chemotherapy for osteosarcoma: a case-control study.
    Song WS; Jeon DG; Cho WH; Kong CB; Cho SH; Lee SY; Lee SY
    J Orthop Sci; 2015 Jan; 20(1):174-9. PubMed ID: 25355661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of dynamic MRI and clinical assessment in predicting histologic response to neoadjuvant chemotherapy in bone sarcomas.
    Amit P; Patro DK; Basu D; Elangovan S; Parathasarathy V
    Am J Clin Oncol; 2014 Aug; 37(4):384-90. PubMed ID: 23388556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Expression of hypoxia-inducible factor 1α in osteosarcoma and its value in predicting chemosensitivity].
    Chen Y; Wang CM; Shi YQ; Yang Y
    Zhonghua Zhong Liu Za Zhi; 2012 Dec; 34(12):899-904. PubMed ID: 23336375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma.
    Bernthal NM; Federman N; Eilber FR; Nelson SD; Eckardt JJ; Eilber FC; Tap WD
    Cancer; 2012 Dec; 118(23):5888-93. PubMed ID: 22648705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
    Hong S; Shin SJ; Jung M; Jeong J; Lee YJ; Shin KH; Roh JK; Rha SY
    Oncology; 2011; 80(1-2):107-17. PubMed ID: 21677455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Place of the pathologist in the management of primary bone tumors (osteosarcoma and Ewing's family tumors after neoadjuvant treatment)].
    Gomez-Brouchet A; Bouvier C; Decouvelaere AV; Larousserie F; Aubert S; Leroy X; Guinebretière JM; Coulomb A; Cassagnau E; de Muret A; Audard V; Marie B; de Pinieux G
    Ann Pathol; 2011 Dec; 31(6):455-65. PubMed ID: 22172118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome.
    Baldini N; Scotlandi K; Barbanti-Bròdano G; Manara MC; Maurici D; Bacci G; Bertoni F; Picci P; Sottili S; Campanacci M
    N Engl J Med; 1995 Nov; 333(21):1380-5. PubMed ID: 7477118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant radiation therapy in resected high-grade localized skeletal osteosarcomas treated with neoadjuvant chemotherapy: Long-term outcomes.
    Sole CV; Calvo FA; Alvarez E; Cambeiro M; Cuervo M; San Julian M; Sole S; Martinez-Monge R; Sierrasesumaga L
    Radiother Oncol; 2016 Apr; 119(1):30-4. PubMed ID: 26970678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma.
    Trieb K; Lechleitner T; Lang S; Windhager R; Kotz R; Dirnhofer S
    Pathol Res Pract; 1998; 194(10):679-84. PubMed ID: 9820863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P16INK4a overexpression and survival in osteosarcoma patients: a meta analysis.
    Bu J; Li H; Liu LH; Ouyang YR; Guo HB; Li XY; Xiao T
    Int J Clin Exp Pathol; 2014; 7(9):6091-6. PubMed ID: 25337256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of p16(INK4a) expression correlates with decreased survival in pediatric osteosarcomas.
    Maitra A; Roberts H; Weinberg AG; Geradts J
    Int J Cancer; 2001 Jan; 95(1):34-8. PubMed ID: 11241308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell Cycle Checkpoints p16 and p21-Strong Predictors of Clinicopathologic Outcomes in High-Grade Osteosarcoma.
    Nasri E; Torrence DE; Vasilopoulos T; Knapik JA; Lagmay JP; Reith JD; Gibbs CP
    Cancer J; 2024 May-Jun 01; 30(3):133-139. PubMed ID: 38753746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Examination of the cutoff value of postchemotherapy increase in tumor volume as a predictor of subsequent oncologic events in stage IIB osteosarcoma.
    Jeon DG; Kong CB; Cho WH; Song WS; Cho SH; Choi SW; Lee SY
    J Surg Oncol; 2014 Mar; 109(3):275-9. PubMed ID: 24243222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Telangiectatic osteosarcoma of the extremity: neoadjuvant chemotherapy in 24 cases.
    Bacci G; Ferrari S; Ruggieri P; Biagini R; Fabbri N; Campanacci L; Bacchini P; Longhi A; Forni C; Bertoni F
    Acta Orthop Scand; 2001 Apr; 72(2):167-72. PubMed ID: 11372948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome.
    Kersting C; Gebert C; Agelopoulos K; Schmidt H; van Diest PJ; Juergens H; Winkelmann W; Kevric M; Gosheger G; Brandt B; Bielack S; Buerger H
    Clin Cancer Res; 2007 May; 13(10):2998-3005. PubMed ID: 17505002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
    Nielsen GP; Burns KL; Rosenberg AE; Louis DN
    Am J Pathol; 1998 Jul; 153(1):159-63. PubMed ID: 9665476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumour response of osteosarcoma to neoadjuvant chemotherapy evaluated by magnetic resonance imaging as prognostic factor for outcome.
    Laux CJ; Berzaczy G; Weber M; Lang S; Dominkus M; Windhager R; Nöbauer-Huhmann IM; Funovics PT
    Int Orthop; 2015 Jan; 39(1):97-104. PubMed ID: 25432323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
    Byun BH; Kong CB; Lim I; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
    J Nucl Med; 2013 Jul; 54(7):1053-9. PubMed ID: 23670899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.